Cargando…

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?

Detalles Bibliográficos
Autores principales:	Bocchi, Edimar Alcides, Rassi, Salvador, Veiga Guimarães, Guilherme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Letter to the Editor ‐ reply
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300805/ https://www.ncbi.nlm.nih.gov/pubmed/30298997 http://dx.doi.org/10.1002/ehf2.12344

Ejemplares similares

Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial
por: Bocchi, Edimar Alcides, et al.
Publicado: (2017)

Hydrotherapy in Heart Failure: A Case Report
por: Carvalho, Vitor Oliveira, et al.
Publicado: (2009)

The Relationship Between Heart Rate Reserve and Oxygen Uptake Reserve in Heart Failure Patients on Optimized and Non-Optimized Beta-Blocker Therapy
por: Carvalho, Vitor Oliveira, et al.
Publicado: (2008)

Reproducibility of the Self-Controlled Six-Minute Walking Test in Heart Failure Patients
por: Guimarães, Guilherme Veiga, et al.
Publicado: (2008)

Heart Rate Dynamics During A Treadmill Cardiopulmonary Exercise Test in Optimized Beta-Blocked Heart Failure Patients
por: Carvalho, Vitor Oliveira, et al.
Publicado: (2008)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Heart Failure in South America
por: Bocchi, Edimar Alcides
Publicado: (2013)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

The course of patients with Chagas heart disease during episodes of decompensated heart failure
por: Issa, Victor Sarli, et al.
Publicado: (2021)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Chagas’ disease: the hidden enemy around the world
por: Bocchi, Edimar Alcides
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Author reply: S‐ICD eligibilities in adults with congenital heart disease
por: Zormpas, Christos, et al.
Publicado: (2021)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Norepinephrine Remains Increased in the Six-Minute Walking Test after Heart Transplantation
por: Guimarães, Guilherme Veiga, et al.
Publicado: (2010)

Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure
por: Scanavacca, Mauricio, et al.
Publicado: (2018)

Reply to Letter to the Editor: “Circulating MicroRNA-423-5p in Hypertensive Patients with Heart Failure: Correspondence”
por: Huang, Ying, et al.
Publicado: (2022)

Quality of Life in Heart Failure: An Important Goal in Treatment
por: Gomes, Brenno Rizerio, et al.
Publicado: (2020)

Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach
por: Issa, Victor Sarli, et al.
Publicado: (2013)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
por: Niu, Chih‐Yuan, et al.
Publicado: (2022)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert, Joseph J, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
por: Rao, Birju R., et al.
Publicado: (2022)

Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
por: Shore, Supriya, et al.
Publicado: (2022)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
por: Abdin, Amr, et al.
Publicado: (2022)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
por: Iovanovici, Diana-Carina, et al.
Publicado: (2022)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
por: Brioschi, Maura, et al.
Publicado: (2023)

Bloqueio do Ramo Esquerdo Idiopático e Sintomas Inexplicáveis Durante o Exercício: Um Relato de Caso
por: Guimarães, Guilherme Veiga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8au21sl51nsqhnp6f8o5cerd43